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Countries in the World Health Organization (WHO) European Region differ in terms of the COVID-
19 vaccine roll-out speed. We evaluated the health and economic impact of different age-based vaccine 
prioritisation strategies across this demographically and socio-economically diverse region. 
 
Methods 
We fitted country-specific age-stratified compartmental transmission models to reported COVID-19 
mortality in the WHO European Region to inform the immunity level before vaccine roll-out. Building 
upon broad recommendations from the WHO Strategic Advisory Group of Experts on Immunisation 
(SAGE), we examined four strategies that prioritise: all adults (V+), younger (20-59 year-olds) followed 
by older adults (60+) (V20), older followed by younger adults (V60), and the oldest adults (75+) (V75) 
followed by incremental expansion to successively younger five-year age groups. We explored four 
roll-out scenarios based on projections or recent observations (R1-4) - the slowest scenario (R1) covers 
30% of the total population by December 2022 and the fastest (R4) 80% by December 2021. Five 
decision-making metrics were summarised over 2021-22: mortality, morbidity, and losses in 
comorbidity-adjusted life expectancy (cLE), comorbidity- and quality-adjusted life years (cQALY), and 




The optimal age-based vaccine prioritisation strategies were sensitive to country characteristics, 
decision-making metrics and roll-out speeds. Overall, V60 consistently performed better than or 
comparably to V75. There were greater benefits in prioritising older adults when roll-out is slow and 
when VE is low. Under faster roll-out, V+ was the most desirable option. 
 
Interpretation 
A prioritisation strategy involving more age-based stages (V75) does not necessarily lead to better 
health and economic outcomes than targeting broad age groups (V60). Countries expecting a slow 
vaccine roll-out may particularly benefit from prioritising older adults. 
Funding 
World Health Organization, Bill and Melinda Gates Foundation, the Medical Research Council (United 
Kingdom), the National Institute of Health Research (United Kingdom), the European Commission, the 
Foreign, Commonwealth and Development Office (United Kingdom), Wellcome Trust 
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Research in Context 
Evidence before this study 
We searched PubMed and medRxiv for articles published in English from inception to 9 Jun 2021, with 
the search terms: (“COVID-19” OR “SARS-CoV-2”) AND (“priorit*) AND (“model*”) AND 
(“vaccin*”) and identified 66 studies on vaccine prioritization strategies. Of the 25 studies that 
compared two or more age-based prioritisation strategies, 12 found that targeting younger adults 
minimised infections while targeting older adults minimised mortality; an additional handful of studies 
found similar outcomes between different age-based prioritisation strategies where large outbreaks had 
already occurred. However, only two studies have explored age-based vaccine prioritisation using 
models calibrated to observed outbreaks in more than one country, and no study has explored the 
effectiveness of vaccine prioritisation strategies across settings with different population structures, 
contact patterns, and outbreak history. 
 
Added-value of this study 
We evaluated various age-based vaccine prioritisation strategies for 38 countries in the WHO European 
Region using various health and economic outcomes for decision-making, by parameterising models 
using observed outbreak history, known epidemiologic and vaccine characteristics, and a range of 
realistic vaccine roll-out scenarios. We showed that while targeting older adults was generally 
advantageous, broadly targeting everyone above 60 years might perform better than or comparably to 
a more detailed strategy that targeted the oldest age group above 75 years followed by those in the next 
younger five-year age band. Rapid vaccine roll-out has only been observed in a small number of 
countries. If vaccine coverage can reach 80% by the end of 2021, prioritising older adults may not be 
optimal in terms of health and economic impact. Lower vaccine efficacy was associated with greater 
relative benefits only under relatively slow roll-out scenarios considered. 
Implication of all the available evidence 
COVID-19 vaccine prioritization strategies that require more precise targeting of individuals of a 
specific and narrow age range may not necessarily lead to better outcomes compared to strategies that 
prioritise populations across broader age ranges. In the WHO European Region, prioritising all adults 
equally or younger adults first will only optimise health and economic impact when roll-out is rapid, 
which may raise between-country equity issues given the global demand for COVID-19 vaccines. 
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The COVID-19 pandemic poses unprecedented challenges to public health, health systems and 
economies globally. Extraordinary efforts and resources have been committed to the development and 
roll-out of COVID-19 vaccines and vaccination programmes.1 These global efforts have led to 
successful vaccine development at an unprecedented speed. 
 
While some countries have signed bilateral advanced purchasing agreements with vaccine 
manufacturers to independently procure enough vaccine doses to cover large proportions of their 
populations, many low- and middle-income countries (LMICs) do not have the resources for such an 
option.2 Globally coordinated efforts to roll out COVID-19 vaccines are therefore required to achieve 
equitable vaccine distribution and to control the COVID-19 pandemic.  
 
The global initiative “COVID-19 Vaccines Global Access” (COVAX) has been set up to ensure 
equitable vaccine access across countries.3 However, the speed at which vaccines become available 
through COVAX is constrained by production and logistical capacities. In the interim vaccine 
distribution forecast published in February 2021, COVAX was projected to deliver vaccines to cover 
approximately 3% of the total population in the 145 COVAX facility participant countries by mid-2021, 
and up to 20% of those populations by the end of 2021.3,4 Among the 53 countries in the WHO European 
Region, 16 Member States may follow this projection as non-Advanced Market Commitment (AMC) 
donors.3 
 
Given the diverse supply conditions, countries in WHO European Region have decided on different 
prioritisation strategies for vaccinating against COVID-19. Besides prioritising healthcare workers 
based on elevated exposure risks, countries have also been recommended to implement age-based 
vaccine prioritisation strategies targeting older adults.5,6 However, the specific age cut-off for “older 
adults” have not been consistent, ranging from 50 to 80 years within the region.7 Some countries have 
not set out to prioritise by age at all.7 Elsewhere in the world, some countries have chosen to prioritise 
younger adults instead. The overall impacts of different vaccine prioritisation strategies under diverse 
supply conditions is, therefore, an instrumental piece of evidence supporting COVID-19 vaccine 
policies. 
 
This study evaluates different age-based vaccine prioritisation strategies given different vaccine supply 
conditions between 2021 and 2022 in the WHO European Region. We identify strategies that maximise 
the health and economic impacts of COVID-19 vaccines, measured by five decision-making metrics 
which allowed us to explore the trade-offs between minimising COVID-19 mortality and morbidity. 
We consider the known epidemiology of SARS-CoV-2, demographic factors, government COVID-19 
response policy stringency, human mobility in each country, and a wide range of hypotheses about 
vaccine mechanisms and characteristics. 
  
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)





Our model framework consisted of two stages (Figure 1). The fitting stage was to estimate the 
proportion of each age group in every country who were no longer susceptible to SARS-CoV-2 by 01 
Jan 2021. The projection stage relied on the results from the fitting stage, vaccine-related assumptions, 
health and economic impact parameters, and projected mobility changes related to expected public 
health and social measures. Using these, we estimated the health and economic outcomes for each 
country under different vaccine supply conditions (expressed as roll-out scenarios) and prioritisation 
strategies by December 2022. 
 
For both stages, we used a previously described COVID-19 compartmental dynamic transmission 
model, CovidM.8 This model includes 16 age groups defined by five-year age bands (from 0-4 to 75+), 
incorporates differences in infectiousness among pre-symptomatic, asymptomatic, and symptomatic 
infections; age-dependent clinical fractions (e.g. the proportion of infected cases that are symptomatic);9 
age-dependent susceptibilities;9 and age-dependent infection-fatality ratios.10 We used country-specific 
population age-structures11 and age-stratified contacts rates12 to capture population dynamics (Figure 2, 
A and B). A complete table summarising input variables and assumptions is presented in Appendix 1.  
 
 
Figure 1. Model Framework 
Caption: This figure describes the overall model framework of the study, which consists of the fitting and 
projection stages. The “known parameters based on existing knowledge” were used in both fitting and projection 
stages. The remaining input was used in only one of the stages as specified. In the conceptual diagram of the 
model: S - Susceptible; E - Exposed; V - Vaccinated; Ev - Exposed among vaccinated; Ip - presymptomatic & 
infectious; Is - symptomatic & infectious; Ia - asymptomatic & infectious; R - Removed. 
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Country-specific infection introduction dates and basic reproduction numbers (R0s) were obtained by 
fitting the model deterministically to reported COVID-19 mortality using maximum likelihood 
estimation (MLE) and differential evolution global optimization algorithms assuming a Poisson 
likelihood function for daily mortality.13 The infection introduction date was constrained to a 90-day 
window before the first reported COVID-19 death in each country. The R0s were constrained to the 1.5 
to 5 range. We also generated 100 stochastic realisations of mortality over time to evaluate the overall 
performance of the fitting stage. 
 
We used smoothed country-specific daily reported COVID-19 mortality (i.e. right-aligned seven-day 
moving averages) based on raw data from the 2019 Novel Coronavirus Visual Dashboard, most of 
which has been collected from the government reports.14 Age-dependent social contact patterns were 
captured by country-specific synthetic contact matrices, which include information from different 
contact settings: work, school, home, and others.12 However, social contacts have deviated substantially 
from their pre-pandemic levels. Thus, we used Google mobility data to approximate the changes in 
contact patterns in work and other settings during the pandemic.15,16 Additionally, social contacts in the 
school setting were based on school-related non-pharmaceutical intervention (NPI) stringency.17 
Contacts at home were assumed to stay unchanged compared to pre-pandemic periods. Please see 
Appendix 2 for more details.  
 
Evidence suggests COVID-19 mortality may have been higher than reported in many countries.18 To 
account for this possibility, we repeated the fitting stage estimating for an additional parameter - a 
country-specific temporally-invariant mortality underreporting rate, as a sensitivity analysis. 
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Figure 2. Key inputs and assumptions. 
Caption: (A) Example population age structure (for the United Kingdom, unit = million).11 (B) 
Example age-specific within-population contact patterns (for the United Kingdom).12 (C) Vaccine roll-
out scenarios and the respective proportions of populations expected to be covered at different time 
points. Note that under different vaccine roll-out scenarios, the starting time of vaccination programs 
may diff. Grey lines in the background represent observed country-level vaccine uptakes (of the first 
dose) over time reported in the WHO European Region.19 (D) Vaccine prioritisation strategies. Hatched 
areas indicate when no vaccine is allocated into the corresponding age groups. (E) Vaccine profiles 
consisting of vaccine efficacy against infection and disease. 
Projection stage 
We assume that social contact patterns (work and other) gradually recover over a year after March 2021 
but never fully return to pre-pandemic levels, due to long-term policies and behavioural changes. Social 
contacts in the school setting followed school terms. More details are presented in Appendix 2. 
 
We examined four roll-out scenarios: R1, R2, R3 and R4 (Figure 2, C). R2 resembles the projected roll-
out projections under COVAX.3,4 In R1, vaccine roll-out is slower and final uptake lower compared to 
R2. Contributors may include production delay, logistical challenges in delivering vaccines, or vaccine 
demand (e.g. vaccine confidence). R1 and R2 both start from 01 Mar 2021. R4 resembles the trajectories 
of the rapid adopters of the region.19 R3 achieves the same coverage as R4, but at a slower pace. R3 and 
R4 both start from 01 Jan 2021. In the WHO European Region, as of July 2021, 29 countries have rolled 
out vaccination at an equal or greater rate than R4, 8 countries at a rate between R3 and R4, 11 countries 
at a rate between R1/2 and R3, and the remaining five countries have not reported vaccine uptake yet.19 
 
We examined four vaccine prioritisation strategies in addition to the counterfactual where no vaccines 
were delivered (V0) (Figure 2, D). In V+, the entire population aged 20+ years received vaccines 
simultaneously. In strategy V20, younger adults (20-59 year-olds) received vaccines before older adults 
(60+ year-olds). In both V60 and V75, older adults (60+ year-olds) were vaccinated first; however, in 
V60 they were all vaccinated simultaneously, whereas in V75 age groups were prioritised in 5-year age 
bands, starting from those above 75 years of age. In this study, the vaccine roll-out of an age group was 
considered complete when 90% of that age group had received a vaccine for 60+ years old and 70% for 
20-59 year-olds. These targets are consistent with optimistic roll-out objectives and intended vaccine 
uptake observed in the WHO European Region.1,20 We additionally explored the condition when 
adolescents (10-19 year-olds) become eligible for the vaccines.  
 
There is still considerable uncertainty around the immunity against SARS-CoV-2. In this study, we 
assumed that vaccinees were protected 14 days following receipt of a vaccine dose.21 Based on a recent 
cohort study,22 we assumed that protection gained from natural SARS-CoV-2 infection would wane 
exponentially with a mean duration of 3 years. For vaccine-induced protection, we assumed it would 
wane exponentially with a mean duration of 52 weeks (with 3 years as sensitivity analysis). Infection-
blocking and disease-reducing mechanisms of vaccines were both modelled. As baseline vaccine 
efficacy (VE), we assume that vaccination prevents 95% of infections and diseases based on the best-
performing vaccines in clinical trials and post-introduction observational data.21,23 Additionally, we 
explored a range of vaccine profiles (see Figure 2, E). The worst performing vaccine we included 
prevented 50% of diseases and had no effect on infection. 
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We used an ordinal logistic regression model to explore if the optimal vaccine prioritisation strategies 
identified are associated with country-specific characteristics such as population sizes, age structures, 
contact patterns, proportions of non-susceptible individuals by 01 Jan 2021, and roll-out scenarios. 
 
Outcomes 
We assessed the impact of different vaccine prioritisation strategies in each country on five health and 
economic decision-making metrics summarised over 01 Jan 2021~31 Dec 2022: (1) mortality, (2) cases, 
(3) comorbidity-adjusted life expectancy (cLE) loss, (4) comorbidity- and quality-adjusted life years 
(cQALY) loss, and (5) value of human capital (HC) loss. The optimal strategy minimises these 
outcomes. Since the top-ranking strategies may have similar effects, we additionally calculated the 
regional totals for each health and economic metric when one strategy is applied to the entire region. 
We briefly define (3)-(5) below and provide more details in Appendix 3. 
 
Comorbidity-adjusted life expectancy (cLE) is a measure of the number of years an individual would 
be expected to live had they not died prematurely, based on the life expectancy of an individual with an 
average level of comorbidities.24 These values are country- and age-specific.  
 
Comorbidity- and quality-adjusted life years (cQALYs) are similar to cLE, but weigh the years someone 
is alive based on their health-related quality of life.25 The cQALY loss due to premature COVID-19 
mortality was calculated using the average age-dependent population norms available for seven 
European countries and country-specific life expectancies, assuming the QALY norms to be the same 
in other countries in the WHO European Region.26 We estimated that each symptomatic COVID-19 
case leads to the loss of 0.0307 QALYs (see Appendix 1), which incorporates detriments due to non-
hospitalised illness episodes, hospitalisations, intensive-care treatment, and post-acute symptoms (long 
COVID). Short-term vaccine side effects were assumed to occur at 50% probability and to lead to a loss 
of 1 quality-adjusted life day per vaccinee.27,28 
 
The human capital (HC) method weighs the number of life-years someone loses by the country-specific 
GDP per capita, as a proxy for the value of that individual’s lost lifetime productivity. These values are 
not adjusted for age or sex, since there is growing consensus that doing so undervalues unpaid labour.29 
We used the World Bank’s country-level GDP per capita estimates.30 
 
The analyses were conducted using R (4.0.4).31 An R Shiny application is available at https://cmmid-
lshtm.shinyapps.io/demo/ to enable users to explore additional sets of parameters not covered in this 
study. 
 
Role of funding source 
The funders of the study had no role in study design; data collection, analysis, and interpretation; 
preparation of the manuscript; or the decision to publish. 
Results 
Model fitting 
Of the 53 WHO European Region Member States, we were able to fit our model to daily reported 
COVID-19 mortality for 38.  The remaining 15 either reported no COVID-19 (n = 1), reported too few 
COVID-19 deaths (<10 deaths/day) to allow reliable inference (n = 12), or had reported major changes 
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to case definitions (n = 2), and were thus excluded from further analyses. The outcomes of the fitting 
process are presented in Figure 3, A-C, using Georgia, Hungary and the United Kingdom as examples. 
Results for all other countries have been archived in our Zenodo repository.32 
 
We found that the inferred infection introduction date in most countries occurred in January 2020 (n 
=38, IQR: 25 Dec 2019, 14 Jan 2020) (Appendix 4). The median R0 estimates was 1.67 (n = 38, IQR: 
1.58, 1.85) (Appendix 4). These estimates are relatively low compared to existing literature,33 possibly 
due to NPIs that are not fully captured by the intensity of mobility and social contacts (e.g. mask-
wearing). Using these inferred parameters, we estimated the median proportion of individuals no longer 
susceptible to SARS-CoV-2 by 01 Jan 2021 to be 13.09% (n = 38, IQR: 6.94%, 21.63%) (Figure 3, D). 
Figure 3. Results of the fitting stage  
Caption: (A-C) Comparisons between observed COVID-19 (purple line), predicted COVID-19 deaths using a 
deterministic realisation using fitted parameters (black line), and 100 stochastic realisations using the same fitted 
parameters (grey lines) in Georgia, Hungary, and the United Kingdom. (D) The estimated proportions of 
individuals no longer susceptible (infectious or recovered) to SARS-CoV-2 infection on 01 Jan 2021 by deciles. 
Countries marked by crosshatch patterns are those that were not included in the fitting stage; countries marked by 
solid grey are outside the WHO European Region. Shapefiles were downloaded from Eurostat GISCO.34 
Optimal prioritisation strategies 
We observed substantial differences in the optimal vaccine prioritisation strategy by decision-making 
metrics. Under R1 and R2, the optimal strategy is V75 to minimise COVID-19 deaths and V20 to 
minimise COVID-19 cases (Figure 4 A-B, F-G). Under R1 and based on cLE, cQALY or HC losses, 
most countries had V60 as their optimal strategy although overall the performance of V+, V20 and V60 
was similar when applied to the entire region, leading to 3-7% more losses compared to when local 
optimal strategies were used (Figure 4, C-E). Under R2, although there were a comparable number of 
countries with V+, V20 and V60 as their optimal strategy based on cLE, cQALY and HC losses, V+ 
was the best performing strategy when applied to the entire region (Figure 4 H-J, Appendix 5). 
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Under R3, V+, V60 and V75 have roughly equal performance when applied to the entire region 
regardless of metric (Figure 4 K-O), leading to an 8-13% increase compared to when the optimal 
strategy for each country was used instead using all metrics. However, under R4, not prioritising by age 
(V+) becomes the optimal strategy in most countries (Figure 4, P-T, Appendix 5). The comparative 
advantage of V+ under R4 is robust to a longer assumed duration of vaccine-induced immunity (i.e. 3 
years) (Appendix 6). 
 
Figure 4. Optimal vaccine prioritisation strategies under different roll-out scenarios and decision-making 
metrics  
Caption: Main panel - Optimal strategies across the WHO European Region that minimise COVID-19 deaths, 
cases, losses in adjusted life expectancy (cLE), quality-adjusted life-years (cQALY), and human capital (HC) as 
decision-making metrics. Top right insert within each panel - y-axis: Difference in outcome (totalled over the 
region) when a given prioritisation strategy is used across the entire WHO European Region compared to if the 
optimal prioritisation strategy in each country is used (black) x-axis: ranking. Sidebars to the right of each panel 
- the proportion of total population for which each prioritisation strategy is optimal. Shapefiles are downloaded 
from Eurostat GISCO;34 countries marked by crosshatch patterns are those that were not included in the projection 
stage. 
 
The results of the ordinal logistic regression show that the only factors that were significantly associated 
with the optimal vaccine prioritisation strategies (with p-values < 0.05) were roll-out scenarios 
(Appendix 7). Faster roll-out scenarios were associated with having optimal strategies that target 
younger or all adults. Additionally, there was weak evidence supporting the association between the 
intensity of adult to older adult contacts with having optimal strategies that prioritise older adults (p-
value < 0.1). 
 
In our sensitivity analysis that incorporated underreporting of COVID-19 mortality, we estimated 
higher proportions of non-susceptible individuals than baseline scenarios. In these cases, the benefits of 
targeting older adults diminished under R3 while other results remained broadly unchanged (Appendix 
8).   
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We noticed that the optimal prioritisation strategies can be sensitive to the decision time frame 
considered after summarising decision metrics over 6, 12, and 18 months following the start of 
vaccination. Although results are robust under R1 and R2, we found substantial variability in optimal 
strategies across decision-making metrics under R3 and R4 (Appendix 9). The temporal cut-off 
presented as the baseline scenario in this study (i.e. drawing a deadline at 2022) was decided through 
discussion with stakeholders. Vaccines may delay upcoming epidemic peaks, and having a temporal 
cut-off may favour later outbreaks over sooner despite epidemic sizes, leading to biased interpretations. 
Lastly, our model shows that vaccinating adolescents with younger adults may bring additional health 
and economic benefits (Appendix 10).  
 
Sensitivity analysis by vaccine characteristics 
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Figure 5. Optimal vaccine prioritisation strategies given different vaccine profiles under R2 and R3. 
Caption: Optimal strategy for each country and vaccine profile while minimising mortality, morbidity, and losses 
in adjusted life expectancy (cLE), quality-adjusted life-years (cQALY), and human capital (HC) for 38 countries 
in the WHO European Region. Countries are arranged in the order of the estimated proportions of the population 
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no longer susceptible to SARS-CoV-2 on 01 Jan 2021 (descending). Countries are labelled by their World Bank 
country codes - a reference table can be found in Appendix 1. 
 
In Figure 5, we present the results under R2 and R3 (additional results under R1 and R4 are presented 
in Appendix 11). The optimal vaccine prioritisation strategy is sensitive to the vaccine profile assumed. 
Under R2, a vaccine product with lower VEs (i.e. profiles 5 and 6) would result in prioritising older 
adults (i.e. V60) being the optimal strategy in many countries in terms of minimising deaths, and losses 
in cLE, cQALY and HC. Under R3 the differences between V+, V60 and V75 are small. The optimal 
strategy varies widely across countries when VE changes. When VE is low (profile 5 and 6), slightly 
more countries had V20, and fewer countries had V+ as their optimal strategy compared to when VE is 
high (profile 1 and 2). 
Discussion 
Using a transmission model of SARS-CoV-2 fitted to reported COVID-19 mortality data in the WHO 
European Region, this study evaluates different vaccine prioritisation strategies under a range of 
possible vaccine roll-out scenarios. We found that age-based vaccine prioritisation strategies with more 
stages do not necessarily perform better. A two-stage approach that prioritises all older adults (V60) 
consistently performs better than or comparably to a five-stage approach that initially prioritises the 
oldest age group and only extends to the next five-year age group younger when vaccination goals of 
the last group have been met (V75). Depending on local context, the choice between V60 and V75 
could depend on other factors beyond health and economic impacts (e.g. ease of roll-out, health system 
characteristics). 
 
We found that when vaccine supply and delivery capacity are in place to reach 80% coverage by the 
end of 2021, the benefits of precisely targeting older adults diminish. Prioritising older adults may be 
more valuable to countries that expect a longer timeline for vaccine uptake to increase (e.g. nearly half 
of the WHO European Region Member States). These findings raise issues around within-country and 
between-country health equity. Countries with sufficient supplies of vaccines may find that they 
maximise benefits domestically by offering vaccination without any age restrictions, as this could 
expedite roll-out. However, there are insufficient supplies of COVID-19 vaccines globally to allow all 
countries to pursue such a strategy. Increased supplies for one country come at the expense of another.35  
 
Evidence on infection-blocking and disease-reducing VE of different vaccine products is emerging. 
Here, we examined six different vaccine profiles, ranging from a highly effective vaccine that prevents 
both infection and disease at 95%, to a vaccine that only prevents 50% of disease and does not provide 
any protection against infection. This range is designed around the vaccine products currently licensed 
in the WHO European Region. If vaccines become disease-reducing but not infection-blocking, more 
countries expecting slower roll-out may prioritise older adults (V60 or V75) given that the severity of 
disease burden increases by age. 
 
Strengths and limitations 
While existing literature focuses on evaluating COVID-19 vaccine prioritisation in any particular city 
or country, our study is the first to investigate the impact of such strategies under different circumstances 
across a large region. We demonstrated that different age structures, contact patterns, and sizes of 
existing epidemics may affect the health and economic impacts of vaccination prioritisation strategies. 
Second, we built our analyses around realistic vaccine roll-out scenarios based on projecting the broad 
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patterns in vaccine roll-out rates across the region. Third, we evaluated a wide range of age-prioritisation 
strategies, not only under different roll-out scenarios but also at different supply levels (e.g. 3%, 20%, 
50% or 80% coverage). The results inform policy recommendations, providing the necessary details for 
continuous implementation. The models and analyses presented here have benefited from continuous 
input since late 2020 from the WHO Regional Office for Europe and technical advisors from many 
countries in the region. Fourth, we included additional decision-making metrics beyond mortality and 
morbidity, providing a more comprehensive assessment of the various trade-offs that need to be 
considered between outcomes.36 Fifth, we considered various vaccine profiles to account for uncertainty 
around vaccine characteristics. Last but not the least, new evidence about vaccine action, changes in 
vaccine supply constraints and the emergence of additional variants of concern (VOCs) may necessitate 
re-evaluation. To facilitate this, we have developed an online tool to help inform such policy decisions.  
 
We did not examine exposure risk- (e.g. highly connected individuals) or occupation-based (e.g., 
healthcare providers) vaccine prioritisation strategies. The evaluation of these strategies requires 
parameters governing their transmission risk (e.g. contact matrices by occupation, coverage and 
effectiveness of personal protective equipment), most of which are not currently available. We did not 
project healthcare system outcomes such as hospital bed and intensive care unit occupancy as there are 
substantial variations across countries and subnational regions in patient pathways, healthcare capacity 
and hospital organisation. 
 
The fitting stage is based on mortality data before 2021, before the start of vaccine roll-out in some 
countries and the large-scale emergence of VOCs that are more transmissible, more clinically severe, 
and potentially immune escaping.37 Future research would require vaccine product-specific uptake 
levels, country-specific underreporting rates for cases (which is far more variable temporally and across 
countries than mortality underreporting), and VOC-specific surveillance data, which are not easily 
available across the WHO European Region.  
 
The fitting stage includes a country-specific temporally-invariant underreporting rate of COVID-19 
mortality as a part of the sensitivity analysis. This rate may be time-varying;38 however incorporating 
time dependencies would likely make parameter identification difficult. The projection stage uses 
constant vaccine efficacy values before Dec 2022, which may not remain valid as VOCs spread, 
although we used a range of vaccine profiles that likely cover performance against the most common 
variants in the WHO European Region as of mid-2021.39 Additionally, we technically modelled the 
vaccine in use as a single-dose product with a 14-day delay between vaccination and effective protection. 




In conclusion, we identified optimal age-based vaccine prioritisation strategies under different vaccine 
roll-out scenarios and vaccine effectiveness profiles at the country level in the WHO European Region. 
We showed that the benefits of prioritising older adults were more evident for relatively slow vaccine 
roll-out scenarios. When prioritising older adults, broadly targeting everyone above 60 years 
consistently performed comparably or better than targeting the oldest adults first followed by the next 
younger five-year age group - the additional stages does not lead to health or economic gains. 
Prioritising younger adults or not prioritising by age is only beneficial when vaccines can be rolled out 
quickly (e.g. reaching 80% of the population vaccinated in 1 year). 
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